ArticleScientific reports2025
Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Metastasis-directed radiotherapy for oligometastatic cervical carcinoma: Identifying potential beneficiaries.Clinical and translational radiation oncology · 2026Article
- Impact of hepatic radiotherapy on survival and safety outcomes in small cell lung cancer patients with liver metastases: a retrospective study.Therapeutic advances in medical oncology · 2026Article
- Case Report: Innovative radiotherapy strategies in advanced colon cancer with oligometastasis: a case of online adaptive radiotherapy and lattice stereotactic re-irradiation.Frontiers in oncology · 2026Article
- Article
- A multi-institutional dummy run on segmentation variability and plan quality of stereotactic body radiotherapy for oligometastatic disease.Physics and imaging in radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data on the efficacy of computer tomography guided brachytherapy (CT-BRT) for limited liver metastases is lacking; to assess CT-BRT's role in inducedoligoprogression in colorectal cancer (CRC), we performed a retrospective cohort study on CRC patients with metastatic disease, treated with 2-5 lines of systemic therapy, who achieved induced oligoprogression with up to four liver metastases eligible for CTBRT. In 75 patients, median overall survival (mOS) was 17 months, and median progression-free survival (mPFS) was 10 months during a 16-month follow-up. The mOS was not dose-dependent. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were found in 8, 31, 47, and 15%, respectively. The mOS in patients with CR, PR, SD, and PD was 23, 17, 14, and 11 months, respectively. Disease Control Rate (DCR) with a high dose influenced OS, while PFS was impacted by extrahepatic metastases (especially in abdominal/pelvic lymph nodes), the number of metastases, and DCR with a high dose. Treatment toxicity was very low (Grade 3-1%, > Grade 3-0%). We report the largest cohort demonstrating CT-BRT as an effective local treatment for colorectal liver metastases in induced oligoprogression, with minimal toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.